When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that ...

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

The prostate inflammation score of biopsy cores is associated with biochemical recurrence risk and might improve prediction of prostate cancer aggressiveness. The degree of inflammation in prostate ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...

- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...